The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2018 | ECHELON-1 AYA subgroup results: brentuximab vedotin plus AVD vs. ABVD
In this interview, Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, of the Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses the Phase III ECHELON-1 trial (NCT01712490) comparing modified (m)PFS obtained with A+AVD vs. ABVD for the frontline treatment of advanced classical Hodgkin lymphoma in adolescents and young adults. Speaking at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Dr Collins reveals the significantly improved mPFS with A+AVD compared with ABVD, before introducing BEACOPP, another treatment option showing improved PFS. Dr Collins explains that, due to variations in efficacy and safety, these three treatment options should be individualized to fit the patient.
